Form 4: Biote Corp. Director Receives Stock Option Grant

Director Bret Christensen was granted 130,000 stock options in Biote Corp. with an exercise price of $2.34.

Summary

• Director Bret Christensen received a grant of 130,000 stock options for Class A Common Stock.
• The options have an exercise price of $2.34 per share.
• The grant date for the transaction was June 8, 2026.
• The options are set to expire on June 7, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of Biote Corp. Class A Common Stock exceeding the $2.34 strike price.

Future Outlook

The options vest on the earlier of June 8, 2027, or the day prior to the 2027 Annual Meeting of Stockholders, contingent on continuous service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and strategic alignment in the biotechnology and healthcare services sectors.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is consistent with standard practices for publicly traded companies of similar size.
• Vesting schedules tied to annual meetings are common in the industry to ensure director retention through the annual cycle.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 8, 2027, or the day prior to the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Biote Corp, BTMD, Director Compensation, Stock Options, SEC Form 4, Insider Transaction